332 related articles for article (PubMed ID: 20074687)
1. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
[TBL] [Abstract][Full Text] [Related]
2. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
[TBL] [Abstract][Full Text] [Related]
3. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
[TBL] [Abstract][Full Text] [Related]
4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
5. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza.
Vodeiko GM; Weir JP
Influenza Other Respir Viruses; 2012 May; 6(3):176-87. PubMed ID: 21902817
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
8. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice.
Fang J; Chen Z; Liu X; Li H; Wang J; Shen X; Chen W; Liu Y; Wang Y; Zhao P; Qi Z
J Virol Methods; 2011 May; 173(2):314-9. PubMed ID: 21392537
[TBL] [Abstract][Full Text] [Related]
10. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination.
Subbramanian RA; Basha S; Shata MT; Brady RC; Bernstein DI
Vaccine; 2010 Dec; 28(52):8258-67. PubMed ID: 21050903
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
[TBL] [Abstract][Full Text] [Related]
12. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
[TBL] [Abstract][Full Text] [Related]
13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
14. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
15. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.
Kreijtz JH; Suezer Y; van Amerongen G; de Mutsert G; Schnierle BS; Wood JM; Kuiken T; Fouchier RA; Lower J; Osterhaus AD; Sutter G; Rimmelzwaan GF
J Infect Dis; 2007 Jun; 195(11):1598-606. PubMed ID: 17471429
[TBL] [Abstract][Full Text] [Related]
16. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies.
Verma S; Soto J; Vasudevan A; Schmeisser F; Alvarado-Facundo E; Wang W; Weiss CD; Weir JP
PLoS One; 2017; 12(4):e0175733. PubMed ID: 28423025
[TBL] [Abstract][Full Text] [Related]
17. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays.
Lorbetskie B; Wang J; Gravel C; Allen C; Walsh M; Rinfret A; Li X; Girard M
Vaccine; 2011 Apr; 29(18):3377-89. PubMed ID: 21397719
[TBL] [Abstract][Full Text] [Related]
18. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.
Shoji Y; Bi H; Musiychuk K; Rhee A; Horsey A; Roy G; Green B; Shamloul M; Farrance CE; Taggart B; Mytle N; Ugulava N; Rabindran S; Mett V; Chichester JA; Yusibov V
Vaccine; 2009 Feb; 27(7):1087-92. PubMed ID: 19100806
[TBL] [Abstract][Full Text] [Related]
19. Avian glycan-specific IgM monoclonal antibodies for the detection and quantitation of type A and B haemagglutinins in egg-derived influenza vaccines.
Legastelois I; Chevalier M; Bernard MC; de Montfort A; Fouque M; Pilloud A; Serraille C; Devard N; Engel O; Sodoyer R; Moste C
J Virol Methods; 2011 Dec; 178(1-2):129-36. PubMed ID: 21907241
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
